Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to evaluate the effect of evolocumab in combination with statin therapy (atorvastatin) in acute ischemic stroke (AIS).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| the evolocumab plus statin therapy | Experimental | Patients with AIS are treated with atorvastatin (40mg) daily and evolocumab (420 mg) every months throughout the study period |
|
| the statin alone therapy | No Intervention | Patients with AIS are treated with atorvastatin (40mg) daily throughout the study period. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Evolocumab | Drug | Patients were randomly assigned of the ratio of 1:1 using a computer-generated random number and divided into two treatment groups: the statin alone therapy and the evolocumab plus statin therapy. |
| Measure | Description | Time Frame |
|---|---|---|
| Percent change in LDL-C | baseline, 4 weeks, 8 weeks, 12 weeks after treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Vascular events | incidence of Transient ischemic attack, stroke or other vascular events | 3 months, 6months |
| mRS (0-2) | proportion of mRS (0-2) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Junli Liang, PhD | Contact | +86-13481138068 | liangjl80@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Junli Liang, PhD | The Second Affiliated Hospital of Guangxi Medical University, Nanning, China | Study Director |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39764289 | Derived | Qiu X, Liang Y, Wei Y, Lu M, Mei Y, Tang S, Tang J, Liang J, Liang J. Evolocumab for early reduction of LDL-C levels in patients with acute ischemic stroke: a randomized controlled trial. Front Neurol. 2024 Dec 23;15:1454608. doi: 10.3389/fneur.2024.1454608. eCollection 2024. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000083242 | Ischemic Stroke |
| ID | Term |
|---|---|
| D020521 | Stroke |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C577155 | evolocumab |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 3 months, 6months |
| death of any causes | proportion of death | 12 months |
| D009422 |
| Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |